Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug

The biotech that has gone all-in on ALS on its way to earning one of the highest neuroscience financing rounds in the last five years is now ready to take the Nasdaq leap.

Amylyx Pharmaceuticals filed its S-1 with the SEC late Thursday, penciling in a $100 million raise estimate to help bring its only product candidate to market. The move comes about five months after Amylyx pulled in $135 million in a Series C.